<DOC>
	<DOCNO>NCT01589445</DOCNO>
	<brief_summary>- The present study undertaken ass efficacy safety two different insulin sensitizer ( namely Pioglitazone Metformin ) among subject type 2 diabetes mellitus ( T2DM ) Bangladesh . - A prospective , double-blind , single group , 'within-subject ' design clinical trial 77 diagnosed T2DM patient 130 patient glycosylated haemoglobin ( HbA1c ) ≥7.2±1.5 % , age 46±6.4 year register diabetes treatment Bangladesh Institute Research Rehabilitation Diabetes Endocrine Metabolic Disorders ( BIRDEM ) carry . - The study conduct November 2008 September 2010 . - Baseline data , include case history patient , anthropometric measurement , biomedical parameter psychosocial factor , collect subject enrolled receive treatment 001 drug daily three month , patient leave wash metformin 850mg daily one month ; receive 002 drug daily three month . - Dietary chart remain . - DNA isolate Chelex method use primer control DNA , restriction Digestion Enzyme Endonuclease Hae 111 genotyping PPARγ- ( Peroxisome Proliferator Activated Receptor gamma ) Pro12Pro - ( Proline12Proline ) /Pro12Ala- ( Proline12 Alanine ) ) /Ala12Ala- ( Alanine12Alanine ) . - The blinded drug decode analyze result , 001 tablet pioglitazone ( 30 mg daily ) 002 tablet metformin ( 850mg daily ) . Bio-medical outcome measure assess efficacy drug month . After finish treatment period effect two drug compare use SPSS.And association pioglitazone drug effect genetic polymorphism also assess . - The metformin effect assess also use response rate HbA1c &lt; 7.0 % 3 month treatment patient .</brief_summary>
	<brief_title>Efficacy Study Pioglitazone Metformin Association Between Pioglitazone Response Peroxisome Proliferator-activated Receptor Gamma Gene Variants Bangladeshi Type 2 Diabetes Mellitus Subjects</brief_title>
	<detailed_description>1 . Introduction Thiazolidinediones metformin know drug especially metformin widely use medicine treat people T2DM . Though pioglitazone suspend many country , safety efficacy matter research drug investigator . Thiazolidinediones introduce 1997 oral anti-diabetic drug ( OAD ) . Metformin use key compound treat T2DM many year prescribe OAD worldwide . Both metformin thiazolidinediones consider `` insulin sensitizer '' . The ß-cell dysfunction insulin resistance core defect progression T2DM associate metabolic syndrome . Evidence suggest pioglitazone lower glucose blood increase glucose uptake cell metformin decrease glucose production . However , many controversy clinical study specially improvement insulin action metformin . In contrast , research recommend pioglitazone appropriate OAD South Asian population . The key argument since pioglitazone proliferator-activated receptor gamma ( PPAR-γ PPARG ) [ group nuclear receptor proteins function transcription factor regulate expression gene ] agonist decrease insulin resistance , overall glycemic control seem good thiazolidinedione . However , publish document efficacy safety drug South Asians . To best knowledge , publish paper examine compare efficacy safety two drug Bangladeshi patient T2DM . This double-blind trail therefore examine efficacy safety pioglitazone metformin T2DM individual also association effect pioglitazone variant PPARG . We compare effect pioglitazone metformin biomedical variable T2DM patient eligible oral hypoglycaemic therapy also analyze association among effect pioglitazone PPARG variant . 2 . Methodology 1 . Study Setting : The study conduct November 2008 September 2010 . The participant study recruit outdoor , BIRDEM Hospital Dhaka , Bangladesh . 2 . Subjects I.Individuals diagnose T2DM treat diet/exercise Metformin 850 mg Pioglitazone 30mg daily , attend Outdoor Patient Department ( OPD ) BIRDEM consultation approach researcher invite participate study . The patient diagnose already register BIRDEM . T2DM ascertain base World Health Organization recommend criterion two repeat measure fast ( plasma glucose ≥7.0 mmol ⁄ l 2-h plasma glucose ≥11.1 mmol ⁄ l. ) II.We screen total 130 patient eligibility select 80 patient enrollment base inclusion exclusion criterion . But 77 T2DM patient HbA1c level &lt; 7.5 % , BMI kg/m2 ≥ 25 , SGPT≤ 100 IU/L , creatinine ≤ 1.2 mg/dl ) sex , age 40-50 , treat monotherapy pioglitazone metformin receive drug trial accord inclusion exclusion criterion . 53 patient screening failure match eligibility criterion ( n=39 ) , refuse take part ( n=11 ) unable take part ( n=03 ) due unknown cause . 3 . Patient Preparation : I.Written inform consent obtain participant study entry . Patients instruct follow adhere disease- weight-orientated diet throughout study . II.Each case history document case report form . The study approve National Medical Ethics Review Boards ( NMERB ) Bangladesh Medical Research Council ( BMRC ) .The investigation carry accordance principle Declaration Helsinki revise 2000 . 4 . Treatment : The patient receive treatment pioglitazone tablet 001 ( 30mg per day ) 3 month follow one month `` metformin wash-out period '' , alternative treatment regimen 3 month metformin tablet 002 ( 850mg per day ) . The drug supply Aristopharma Pharmaceutical Ltd. , Bangladesh . 5 . Anthropometric Measurements I.Height : Standing height measure use appropriate scale ( Detect-Medic , Detect scale INC , USA ) without shoe . II.Weight : Weight measure balance place hard flat surface check zero balance measurement . The subject center platform wear light cloth without shoe . III.BMI : Body mass index ( BMI ) subject calculate use standard formula : BMI= Weight ( kg ) / [ Height ( ) ] 2 . IV.Blood Pressure : Systemic Diastolic pressure measure accord WHO-IHS . 6 . Blood Sample Collection Biochemical analysis : I . During appoint date patient come fasting condition . Fasting blood sample ( 10 ml ) drawn antecubital vein . The time mention 0 hour . Then patient receive drug . They request swallow tablet breakfast accord diet chart . Next blood sample draw 30 min 2 hour provide drug whole month . II.The patient request take drug breakfast every day 29 day . III.From fast blood sample 1ml blood transfer EDTA contain tube measurement HbA1C rest blood take EDTA contain tube centrifuge immediately . IV.Samples process divide two aliquot sterile condition ; one aliquot send biochemical analysis Fasting glucose , Lipid profile , Cholesterol , ALT , Insulin , Creatinine another one store -80 0C verification result case necessity . 7 . Biochemical Test Methods : I. Serum glucose ( fast , 1 2 hour ) Glucose Oxidase ( GOD-PAP ) method ( Randox Laboratories Ltd. , UK ) . II.Serum triglyceride enzymatic colorimetric ( GPO-PAP ) method ( Randox Laboratories Ltd. , UK ) . III.Serum total cholesterol enzymatic endpoint ( Cholesterol Oxidase/ Peroxidase ) method ( Randox Laboratories Ltd. , UK ) . IV.Serum HDL cholesterol enzymatic colorimetric ( Cholesterol CHOD-PAP ) method ( Randox Laboratories Ltd. , UK ) use micro-plate reader ( Bio-Tec , ELISA ) . V.Serum creatinine enzymatic colorimetric ( GPO-PAP ) method ( Randox Laboratories Ltd. , UK ) . VI.Serum alanine amino transferase ( ALT ) UV method use ALT ( GPT ) opt.kit ( Randox Laboratories Ltd. , UK ) . VII.Serum insulin enzyme link immunosorbent assay ( ELISA ) method ( Linco Research Inc. , USA ) . VIII.Glycosylated Haemoglobin ( HbA1c ) High Performance Liquid Chromatographic ( HPLC ) method . 8 . Blood sample collection DNA analysis ( PPARG gene ) : I.At end 3rd month treatment 1.5 ml blood take EDTA contain tube genetic analysis whole blood specimen collect vacuum collection tube contain EDTA , store -20 0C - 80 0C . II.DNA isolate Chelex method , identify electrophoresis method amplify use primer . We use publish document select primer genotyping PPARγ Pro12Ala/Pro12Pro . The primer Pro12Ala SNP genotype , amplify exon B use reverse primer 5 ' CTG GAA GAC AAA CTA CAA GAG 3 ' forward primer 5 ' ACT CTG GGA GAT TCT CCT ATT GGC 3 ' . ( Sigma product , Order No . SIGMA 03/11/09 4152936-F/185 PPARG-R 8006875247-1 ) . III.Control DNA : Professor Colin Palmer Laboratory , Biomedical Research Institute , University Dundee Medical School , University Dundee , Scotland , UK send six control sample 3 type control DNA genotyped PPARG SNP rs 1801282 ( Pro12Ala ) . IV.Restriction Digestion Enzyme Endonuclease Hae 111 use identify cut site ( Sigma Product No . R 5628 ) . 3 . Response Rate : 1 . The response rate define decrease ≥10 % FBG decrease ≥1 % HbA1c baseline value . ll.There another response group define HbA1c rate &lt; 7.0 % 3 month treatment metformin find secondary failure rate metformin . 4 ) Statistical Analysis : I.Statistical analysis perform use SPSS ( Statistical Package Social Science ) software Windows version 18 ( SPSS Inc , Chicago , Illinois , USA ) . Data express mean + SD ( Standard Deviation ) . II . Effects drug 3 month treatment analyze use pair test . The group compare use one way ANOVA . If p value &lt; 0.05 , group compare use student 's test unpaired sample χ2 test univariate analysis verification . Correlation coefficient among variable test use Pearson 's test . Multivariate logistic regression analysis perform obtain odds ratio independent influence factor find possible association PPARγ genotypes drug response case genetic analysis . III.A p value &lt; 0.05 consider significant test . lv . The statistical analysis within group study like PPARG response group metformin secondary failure group display . 5 ) List Abbreviations AEs Adverse Events ALT Alanine aminotransferase BMI Body Mass Index BMRC Bangladesh Medical Research Council BIRDEM Bangladesh Institute Research Rehabilitation Diabetes , Endocrine Metabolic Disorder BP Blood Pressure DNA Deoxynucleic Acid DBP Diastolic Blood Pressure DM Diabetes Mellitus EASD European Association Study Diabetes EDTA Ethylene Diamine Tetra Acetic acid ELISA Enzyme Linked Immunosorbent Assay FBG/FSG Fasting Blood Glucose/Fasting Serum Glucose FSI Fasting Serum Insulin 2hBG 2 hour Blood Glucose HbA1c Glycosylated Haemoglobin HOMA percent B Homeostasis Model Assessment percentage beta cell function HOMA percent S Homeostasis Model Assessment percentage sensitivity HOMA IR Homeostasis Model Assessment Insulin Resistance HDL-C High Density Lipid Cholesterol IU/L International Unit/Litre LDL-C Low Density Lipid Cholesterol ml millilitre mm millimetre mg/dl milligram/ decilitre MLR Multiple Logistic Regression OPD Outdoor Patient Department OMIM Online Mendelian Inheritance Man OR Odds Ratio PPARγ Peroxisome Proliferator Activated Receptor gamma Pro12Pro Proline12Proline Pro12Ala Proline 12 Alanine Ala12Ala Alanine12Alanine PCR Polymerase Chain Reaction QUICKI Quantitative Insulin sensitivity Check Index SD Standard Deviation SPSS Statistical Package Social Science SBP Systolic Blood Pressure TC Total Cholesterol TG Triglyceride T2DM Type 2 Diabetes Mellitus TZD Thiazolidinedione µl Microliter WHO World Health Organization</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 DM patient ( HbA1c level &lt; 8.5 % , BMI kg/m2 ≥ 25 , SGPT ≤ 100 IU/L , creatinine ≤ 1.2 mg/dl ) sex , Aged 4050 , Treated monotherapy pioglitazone metformin . Patients diabetes secondary another cause . Patients suffer serious incurrent illness require systemic treatment . Patients suffer infectious disease . Patients impaired kidney function ( serum creatinine level 1.2mg/dl ) Patients impaired hepatic function ( SGPT ≥ 100 IU/L ) . Patients pulmonary insufficiency hypoxaemia . Triglyceriadiamea ( TG ≥ 150mg/dl ) . Bloodpressure &gt; 180 mmHg ( Systolic ) &gt; 110 mmHg ( diastolic ) . Positive history drug alcohol abuse . Pregnant woman willing pregnant shortly .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Bangladesh</keyword>
	<keyword>T2DM</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Metformin</keyword>
	<keyword>Insulin secretion Sensitivity</keyword>
</DOC>